Tissue factor pathway inhibitor: From unknown coagulation inhibitor to major antithrombotic principle

Cardiovascular Research

Volumn 33, Issue 2, 1997, Pages 286-291

  Lindahl, Anne Karin ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

thrombosis; tissue factor pathway inhibitor

Indexed keywords

TISSUE FACTOR PATHWAY INHIBITOR;

HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR XA; HUMANS; LIPOPROTEINS; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 0031015687     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(96)00208-8     Document Type: Review

References (44)

1. Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987;69:645-651.
2. Broze GJ, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987;69:150-155.
3. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988;71:335-343.
4. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988;263:6001-6004.
5. Enjyouji KI, Emi E, Mukai T, et al. Human tissue factor pathway inhibitor (TFPI) gene: complete genomic structure and localization on the genomic map of chromosome 2q. Genomics 1993;17:423-428.
6. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of the lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520.
7. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze J Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993;4:661-669.
8. Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 1993;4:713-720.
9. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989;264:18832-18837.
10. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991;2:425-433.
11. Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coagul Fibrinolysis 1994;5:819-823.
12. Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991;64:155-168.
13. Novotny WF, Brown S, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-393.
14. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992;3:439-449.
15. Sandset PM, Røise O, Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in postoperative/posttraumatic septicaemia: increased levels in fatal cases. Haemostasis 1989;19:189-195.
16. Hamamoto T, Yamamoto M, Nordfang O, Petersen JGL, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). J Biol Chem 1993;268:8704-8710.
17. Lindahl AK, Jacobsen PBJ, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 1991;2:713-721.
18. Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemostas 1994;71:275-279.
19. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BH. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995;44;80-84.
20. Weissbach G, Harenberg J, Wendisch J, Pargac N, Thomas K. Tissue factor pathway inhibitor in infants and children. Thromb Res 1994;73:441-446.
21. Sandset PM, Lund H, Norseth J, Ose L, Abildgaard U. Treatment with HMC-CoA reductase inhibitor in hypercholesterolaemia induces changes in the components of the extrinsic coagulation system. Arterioscl Thromb 1991;11:138-145.
22. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992;79:3219-3226.
23. van der Logt CPE, Dirven RJ, Reitsma PH, Bertina RM. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinolysis 1994;5:211-220.
24. Lesnick P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993;13:1066-1075.
25. Moor E, Hamsten A, Karpe F, Båvenholm P, Blomback M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemostas 1994;71:707-712.
26. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988;50:803-813.
27. Valentin S, Larnkjer A, Østergaard P, Nielsen JI, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994;75:173-183.
28. Maaoui A, Connard J, Samama MM. Tissue factor pathway inhibitor (TFPI) during prolonged treatments by unfractionated (UH) or low molecular weight heparin (LMWH). Thromb Haemostas 1993;69:681(Abstract).
29. Iversen N, Sandset PM, Abildgaard U, Rao V, Nordfang O. Binding of recombinant tissue factor pathway inhibitor (rTFPI) to endothelial cells: influence of glycosaminoglycans. Thromb Haemostas 1993;69:644(Abstract).
30. Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990;59:651-656.
31. Kalbas M, Hinz U, Muller-Berghaus G. Heparin-induced release of tissue factor pathway inhibitor (TFPI) by human endothelial and malignant cells. Thromb Haemostas 1993;69:681(Abstract).
32. Sandset PM, Warn-Cramer BJ, Rao VML, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiological role of EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991;88:708-712.
33. Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemostas 1991;66:464-467.
34. Erhardsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced hemophilia A. Blood Coag Fibrinolysis 1995;6:388-394.
35. Bregengaard C, Nordfang O, Østergaard P, et al. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemostas 1993;70:454-457.
36. Day KC, Hoffman LC, Palmier MO, et al. Recombinant lipoprotein associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990;76:1538-1545.
37. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2860.
38. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coagul Fibrinolysis 1994;5:819-823.
39. Haskel EJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein- associated coagulation inhibitor. Circulation 1991;84:821-827.
40. Khoury RK, Koudsi B, Kaiding F, Ornberg RL, Wun TC. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg 1993;30:398-404.
41. Lindahl AK, Nordfang O, Wildgoose P, Kelly AB, Harker LA, Hanson SR. Antithrombotic effects of a truncated tissue factor pathway inhibitor (TFPI) in baboons. Thromb Haemostas 1993;69:742(Abstract).
42. 1-161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb Haemostas 1994;71:214-219.
43. Lindahl AK, Wildgoose P, Lumsden AB, et al. Active site-inhibited factor Vila blocks tissue factor activity and prevents arterial thrombus formation in baboons. Circulation (suppl) 1993;88:I-417(Abstract).
44. Jang Y, Guzman LA, Lincoff M, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-3050.